This company listing is no longer active
Destiny Pharma Management
Management criteria checks 3/4
Destiny Pharma's CEO is Chris Tovey, appointed in Sep 2023, has a tenure of less than a year. total yearly compensation is £123.00K, comprised of 89.4% salary and 10.6% bonuses, including company stock and options. directly owns 0.042% of the company’s shares, worth €1.40K. The average tenure of the management team and the board of directors is 3.4 years and 6.3 years respectively.
Key information
Chris Tovey
Chief executive officer
UK£123.0k
Total compensation
| CEO salary percentage | 89.4% |
| CEO tenure | less than a year |
| CEO ownership | 0.04% |
| Management average tenure | 3.4yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | UK£123k | UK£110k | -UK£6m |
Compensation vs Market: Chris's total compensation ($USD157.25K) is below average for companies of similar size in the German market ($USD531.21K).
Compensation vs Earnings: Insufficient data to compare Chris's compensation with company performance.
CEO
Chris Tovey (59 yo)
less than a year
Tenure
UK£123,000
Compensation
Mr. Christopher John Tovey, also known as Chris, BSc, serves as Chief Executive Officer & Director of Destiny Pharma plc since September 1, 2023. He had been the Chief Operating Officer at GW Pharmaceutica...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | UK£123.00k | 0.042% € 1.9k | |
| Founder | 27.6yrs | UK£250.00k | 6.8% € 309.2k | |
| CFO, Company Secretary & Director | 5.8yrs | UK£270.00k | 0.025% € 1.2k | |
| Interim CMO & Senior Independent Director | less than a year | UK£213.00k | 0.092% € 4.2k |
3.4yrs
Average Tenure
60.5yo
Average Age
Experienced Management: D89's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | UK£123.00k | 0.042% € 1.9k | |
| Founder | no data | UK£250.00k | 6.8% € 309.2k | |
| CFO, Company Secretary & Director | 5.8yrs | UK£270.00k | 0.025% € 1.2k | |
| Interim CMO & Senior Independent Director | 4.6yrs | UK£213.00k | 0.092% € 4.2k | |
| Independent Chairman | 8yrs | UK£34.00k | 3.93% € 178.7k | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Non-Executive Director | 2.2yrs | UK£41.00k | 0.36% € 16.6k | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Chair of the Scientific Advisory Board | 6.3yrs | UK£10.66k | no data | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
6.3yrs
Average Tenure
62yo
Average Age
Experienced Board: D89's board of directors are considered experienced (6.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/13 13:35 |
| End of Day Share Price | 2024/08/14 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Destiny Pharma plc is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian White | Cantor Fitzgerald Europe |
| Nathaniel Calloway | Edison Investment Research |
| Brian White | Shore Capital Group Ltd |